Oxford BioDynamics Plc (LON:OBD – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 0.08 and last traded at GBX 0.11, with a volume of 19840916 shares changing hands. The stock had previously closed at GBX 0.11.
Oxford BioDynamics Trading Up 3.8%
The firm has a market capitalization of £4.72 million, a price-to-earnings ratio of -0.55 and a beta of 0.42. The business’s 50-day moving average price is GBX 0.18 and its 200 day moving average price is GBX 0.22. The company has a debt-to-equity ratio of 131.61, a current ratio of 2.01 and a quick ratio of 2.80.
Oxford BioDynamics (LON:OBD – Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The biotechnology company reported GBX (0.10) EPS for the quarter. Oxford BioDynamics had a negative return on equity of 451.74% and a negative net margin of 825.61%.
Oxford BioDynamics Company Profile
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Recommended Stories
- Five stocks we like better than Oxford BioDynamics
- Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
- KBR Insiders Are Buying While the Market Misreads Its Spinoff
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
